Company / Gross Margin
Halozyme Gross Margin History
FY2016-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
6.6%
FY2019
5-year range
-
FY2016-FY2019
Trend
-45.9%
vs FY2018
Sector context
#29 of 28
Health Care
What the data says
Among 28 Health Care companies, Halozyme is in the bottom -4% for gross margin. Improved from 1.2% to 6.6% over the past 2 years.
Based on SEC 10-K filings.
6.6% in FY2019 with a 3-year CAGR of +2.1%.
Improved from 1.2% to 6.6% over the past 2 years.
Health Care sector context is included.
Gross Margin over time
Growth rates
- 3-Year Change
- +2.1pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Bottom -4% in Health CareTop 104% of 28This company 6.6% Sector average 60.3%
▼
-89.1% below sector average
Key checks
Key Insights
- In FY2019, gross margin decreased 45.9% year-over-year.
- Currently 53.7pp below the Health Care sector average.
Company context
Key Data Points
- Strong profit margin: 47.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 118.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | 6.6% | -45.9% |
| FY2018 | 12.1% | +887.0% |
| FY2017 | 1.2% | -72.5% |
| FY2016 | 4.5% | -27.2% |
As of FY2019 · SEC 10-K · Updated Jun 30, 2026